Incyclix Bio is a next-generation cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. The company's lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/25/25 | $11,250,000 | Series B Extension |
Cape Fear BioCapital Eli Lilly and Company Eshelman Ventures Pharmacosmos | undisclosed |
